Publications by authors named "David Modrak"

Claim this Profile
D
Detection of early-stage pancreatic adenocarcinoma.
David V Gold, Michael Goggins, David E Modrak, Guy Newsome, Mengling Liu

Cancer Epidemiol Biomarkers Prev· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines.
David E Modrak, Evelyn Leon, David M Goldenberg, David V Gold

Mol Cancer Res· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
David V Gold, Zarir Karanjawala, David E Modrak, David M Goldenberg, Ralph H Hruban

Clin Cancer Res· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sphingolipid targets in cancer therapy.
David E Modrak, David V Gold, David M Goldenberg

Mol Cancer Ther· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis.
David V Gold, David E Modrak, Zhiliang Ying, Thomas M Cardillo, Robert M Sharkey

J Clin Oncol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a Mu-9 (anti-colon-specific antigen-p)-reactive peptide having homology to CA125 (MUC16).
David E Modrak, Habibe Karacay, Thomas M Cardillo, Guy Newsome, David M Goldenberg

Int J Oncol· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurement of ceramide and sphingolipid metabolism in tumors: potential modulation of chemotherapy.
David E Modrak

Methods Mol Med· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer.
David E Modrak, Thomas M Cardillo, Guy A Newsome, David M Goldenberg, David V Gold

Cancer Res· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
Thomas M Cardillo, Habibe Karacay, David M Goldenberg, Dion Yeldell, Chien-Hsing Chang, David E Modrak

Clin Cancer Res· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft.
David V Gold, David E Modrak, Keith Schutsky, Thomas M Cardillo

Int J Cancer· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression.
Rosalyn D Blumenthal, Evelyn Leone, David M Goldenberg, Marisol Rodriguez, David Modrak

Int J Cancer· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.
David V Gold, Keith Schutsky, David Modrak, Thomas M Cardillo

Clin Cancer Res· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts.
David E Modrak, Marisol D Rodriguez, David M Goldenberg, Walter Lew, Rosalyn D Blumenthal

Int J Oncol· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis